An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Silexan is a lavender oil preparation in gelatine capsules containing 80 mg. We reviewed the clinical trials investigating the anxiolytic efficacy and tolerability of Silexan as well as its safety and potential for drug interactions. METHODS: Seven trials were included, among which four therapeutic trials had a treatment duration of 6 or 10 weeks. RESULTS: In patients with subsyndromal anxiety or generalised anxiety disorder (GAD) an anxiolytic effect of Silexan was evident after 2 weeks. Patients treated with Silexan showed Hamilton Anxiety Scale (HAMA) total score decreases between 10.4 ± 7.1 and 12.0 ± 7.2 points at Week 6 and between 11.8 ± 7.7 and 16.0 ± 8.3 points at Week 10. CONCLUSIONS: HAMA total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subsyndromal anxiety and comparable to lorazepam in its starting dose in patients with GAD. Silexan had beneficial effects on typical co-morbidity symptoms of anxiety disorders, for example, disturbed sleep, somatic complaints, or decreased quality of life. Except for mild gastrointestinal symptoms, the drug was devoid of adverse effects and did not cause drug interactions or withdrawal symptoms at daily doses of 80 or 160 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Instrument For Anxiety Disorders
Zung, W. W. K. (1971) · Psychosomatics · doi:10.1016/s0033-3182(71)71479-0 · Cited by 4,578 · cited 1×
“Th e investigators ’ assessment of anxiety using the HAMA was complemented by the patient-rated Zung Self-rating Anxiety Scale (SAS, Zung 1971).”
MethodThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“According to a recent study, the three most prevalent mental disorders in the European Union are anxiety disorders, insomnia, and major depression, with 12-month prevalence rates of 14%, 7%, and 6.9%, respectively (Wittchen et al. 2011).”
BackgroundInfluentialCognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312 · cited 1×
“Synthetic anxiolytic drugs, notably benzodiazepines, have been associated with unwanted sedative, addictive and withdrawal eff ects (Buff ett-Jerrott and Stewart 2002; Iguchi et al. 1993; Onyett 1989; Petursson 1994).”
BackgroundThe benzodiazepine withdrawal syndrome
PÉTURSSON, H. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03743.x · Cited by 246 · cited 1×
“Synthetic anxiolytic drugs, notably benzodiazepines, have been associated with unwanted sedative, addictive and withdrawal eff ects (Buff ett-Jerrott and Stewart 2002; Iguchi et al. 1993; Onyett 1989; Petursson 1994).”
BackgroundReduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters
Engström, G., Alling, C., Blennow, K., Regnéll, G., & Träskman-Bendz, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00016-4 · Cited by 157
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · cited 1×
“In study G the Physician Withdrawal Checklist (PWC-20, Rickels et al. 2008), that was originally developed to detect benzodiazepine-like withdrawal symptoms caused by anxiolytics of the non-SSRI type, was evaluated at the end of the 10-week randomised treatment period as well as 1 week thereaft er.”
Method
Cited by
Cimino, C., Maurel, O. M., Musumeci, T., Bonaccorso, A., Drago, F., Souto, E. M. B., Pignatello, R., & Carbone, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030327 · Cited by 324
The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice
Möller, H.-J., Bandelow, B., Volz, H.-P., Barnikol, U. B., Seifritz, E., & Kasper, S. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0684-7 · Cited by 127
Self-citationFedotova, J., Kubatka, P., Büsselberg, D., Shleikin, A. G., Caprnda, M., Dragasek, J., Rodrigo, L., Pohanka, M., Gasparova, I., Nosal, V., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.107 · Cited by 59
Trkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Metadata
- Authors
- Kasper, S.
- Venue
- International Journal of Psychiatry in Clinical Practice
- Publisher
- Informa UK Limited
- Published
- 2013-08-03
- Volume
- 17
- Issue
- sup1
- Pages
- 15-22
- ISSN
- 1365-1501 (ISSN-L)
- 1471-1788
- OpenAlex
- W2018117242
- Cited by
- 57
- References
- 6
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. https://app.cochat.ai/papers/10.3109/13651501.2013.813555
- The paper
- Kasper, S. (2013). An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.3109/13651501.2013.813555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.